PRS-CSx estimated posterior meta-analysis effect sizes for 1 126 428 variants and they were used to calculate PRSall. In total, there were 1 533 variants with P-values < 0.05 in both EA-PAU and AA-AUD and having the same directions of effects (i.e., concordant). Among them, 858 (Table S1) and 675 (Table S3) variants were located within (410 genes, Table S2) and outside gene boundaries, respectively. As shown in Table 2, for AA target datasets, both PRSgene and PRSall had P-values < 0.05 in all target datasets except PRSall for COGA. PRSintergnic had P-values ≥ 0.10 in all target datasets, demonstrating that concordant variants located within genes better stratify risk for AUD than those located in intergenic regions. Effect sizes ranged from 0.15-0.21 for PRSgene, −0.02 to 0.12 for PRSintergenic, and 0.06-0.18 for PRSall, respectively. In EA, 847 of 858 variants (Table S1), and 1 061 130 of 1 126 428 variants were present in Indiana Biobank after QC; both PRSgene and PRSall had P-values < 0.05 (PRSgene Beta=0.11, SE = 0.02; PRSall Beta = 0.34, SE = 0.05) but not
